Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Affiliations

• ¹ Gynecologic Oncology and Leuven Cancer Institute, and Department of Oncology, KU Leuven, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. evelyndespierre@gmail.com.
• ² Gynecologic Oncology and Leuven Cancer Institute, and Department of Oncology, KU Leuven, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
• ³ University of Colorado Cancer Center, Aurora, Colorado, USA.
• ⁴ EORTC Headquarters, Brussels, Belgium.
• ⁵ Azienda Ospedaliera, Presidio Santa Anna, SCDO 3 Ginecologia Oncologica, Università di Torino, Turin, Italy.
• ⁶ Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Leuven, Belgium.
• ⁷ Vesalius Research Center (VRC), VIB, Leuven, Belgium.
• ⁸ Academic Division of Gynecological Oncology, Mauriziano Hospital, Turin, Italy.
• ⁹ Département d'Oncologie Médicale Adulte, Centre Leon Bérard, Lyon, France.
• ¹⁰ Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool Clatterbridge Centre for Oncology, Bebington, Merseyside, CH63 4JY, United Kingdom.
• ¹¹ Border Medical Oncology, 1/69 Nordsvan Drive, Wodonga, Victoria, 3690, Australia.
• ¹² Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
• ¹³ Hospital Universitario Clínico San Carlos, Servicio de Oncologia Medica, Madrid, Spain.